A theranostic approach based on radiolabeled antiviral drugs, antibodies and CRISPR-associated proteins for early detection and treatment of SARS-CoV-2 disease
- PMID: 32796470
- PMCID: PMC7485524
- DOI: 10.1097/MNM.0000000000001269
A theranostic approach based on radiolabeled antiviral drugs, antibodies and CRISPR-associated proteins for early detection and treatment of SARS-CoV-2 disease
Conflict of interest statement
There are no conflicts of interest.
Comment on
-
Incidental Findings Suggestive of COVID-19 in Asymptomatic Patients Undergoing Nuclear Medicine Procedures in a High-Prevalence Region.J Nucl Med. 2020 May;61(5):632-636. doi: 10.2967/jnumed.120.246256. Epub 2020 Apr 1. J Nucl Med. 2020. PMID: 32238429
References
-
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020; 323:1239–1242 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
